399O Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial
Gerardo Rosati(Ospedale San Carlo), Roberto Labianca(Ospedale Papa Giovanni XXIII), Valeria Pusceddu(University of Cagliari), Katia Dotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Monica Ronzoni, Francesca Galli(University of Modena and Reggio Emilia), L. Ciuffreda(Azienda Ospedaliero Universitaria San Giovanni Battista), Alfonso De Stefano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Felice Pasini(Ospedale Civile Di Ivrea), Sara Elena Rebuzzi(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Sara Lonardi(Istituto Oncologico Veneto), Silvia Bozzarelli(IRCCS Humanitas Research Hospital), Carla Codecà(Ospedale San Paolo), Nicoletta Pella(University of Udine), Andrea Mambrini, Maria Giulia Zampino(Azienda Ospedaliera Universitaria Pisana), Maria Banzi(Azienda Ospedaliera S.Maria), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Vincenzo Montesarchio(CTO Hospital)
Cited by 5
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k